Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

PMV Pharmaceuticals, Inc. PMVP on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.As of the data cutoff date of August 4, 2025, the safety population consisted of 109 patients treated with at least one dose of rezatapopt 2000 mg daily as monotherapy.EfficacyConfirmed responses were observed in patients whose tumors were TP53 Y220C mutated and KRAS wild-type in eight tu ...